Recent News for DDDD - 4D Pharma Plc

Date Title
Apr 19 4D pharma Collaborates With Parkinson’s UK to Establish Patient Advisory Board
Apr 1 Final Results for the year ended 31 December 2020
Mar 22 4D pharma Announces Completion of Merger With Longevity Acquisition Corporation
Mar 22 Completion of Merger With Longevity Acquisition Corporation and Admission of American Depositary Shares to Trading on NASDAQ
Mar 17 4D Pharma Announces Private Placement
Mar 3 4D Pharma to Present at Upcoming Investor Conferences in March
Mar 1 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director
Mar 1 4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team
Feb 26 4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ
Feb 16 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
Feb 8 4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Feb 3 4D Pharma Presents Update on Oncology Program
Jan 27 Could The 4D pharma plc (LON:DDDD) Ownership Structure Tell Us Something Useful?
Jan 21 4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe
Dec 21 Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative
Nov 27 4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)
Back to the Main DDDD Page...